Promising New Alzheimer’s Drugs Face Questions About Real-World Benefit

May 15, 2023

(Axios) – Promising clinical trial results from another new Alzheimer’s drug haven’t put to bed questions about how much the treatments actually benefit patients, and whether their strong points outweigh their safety risks. Why it matters: Preliminary data for Eli Lilly’s donanemab make potentially the best case so far that scientists have found a drug that slows the progression of Alzheimer’s disease, a condition with no cure that affects about 50 million people worldwide. (Read More)